SOHO 2024 | Dr. Grzegorz S. Nowakowski Discusses the Latest Advances in First-line Treatment of DLBCL

SOHO 2024 | Dr. Grzegorz S. Nowakowski Discusses the Latest Advances in First-line Treatment of DLBCL

Diffuse large B-cell lymphoma (DLBCL), as the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and poses challenges in treatment. Patient prognosis is influenced by various factors, and while the standard R-CHOP regimen is widely used, its efficacy is limited for high-risk groups such as patients with double-hit lymphoma (DHL), necessitating more precise treatment plans. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place from September 4th to 7th, 2024, in Houston, USA, attracting top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new strategies for treatment. During the conference, "Hematology Frontier" specially invited Dr. Grzegorz S. Nowakowski from the Mayo Clinic Comprehensive Cancer Center to analyze the latest advances in the treatment of DLBCL and the future direction of treatment strategies, aiming to provide important guidance for clinicians in optimizing treatment plans and making precise therapeutic choices.
World Leukemia Day: Building a Health Defense, Lighting the Flame of Life

World Leukemia Day: Building a Health Defense, Lighting the Flame of Life

September 4 marks "World Leukemia Day," an initiative launched by the Acute Leukemia Advocates Network, CLL Advocates Network, CML Advocates Network, and Leukaemia Care. The day is dedicated to raising global awareness about leukemia, promoting efforts in prevention, diagnosis, treatment, and recovery. Leukemia, often called "blood cancer," is a complex disease with high treatment costs and the risk of relapse, placing a heavy burden on many families. However, through awareness and action on this day, we aim to break the silence and helplessness, and collectively ignite a beacon of hope for leukemia patients.
Dr. Jin Gu: Significant Benefits of Combined Pelvic Organ Resection for High-Risk Locally Advanced Rectal Cancer | Guangzhou Colorectal Cancer Summit

Dr. Jin Gu: Significant Benefits of Combined Pelvic Organ Resection for High-Risk Locally Advanced Rectal Cancer | Guangzhou Colorectal Cancer Summit

From August 5th to 10th, 2024, the Guangzhou Colorectal Cancer Summit Forum and the 22nd Guangdong Provincial Colorectal Cancer Academic Conference were held in Guangzhou. During the event, Dr. Jin Gu from Peking University Shougang Hospital shared important insights and conclusions from his center’s experience with combined pelvic organ resection surgery for refractory rectal cancer. After the conference, we had the privilege of interviewing Professor Gu.
CSCO 2024丨Dr. Jiong Wu: INAVO120 Accelerates the Approval of New PI3Ki Inavolisib by CDE, Gene Testing Propels the Era of Precision Targeted Therapy

CSCO 2024丨Dr. Jiong Wu: INAVO120 Accelerates the Approval of New PI3Ki Inavolisib by CDE, Gene Testing Propels the Era of Precision Targeted Therapy

Hormone receptor-positive (HR+) breast cancer is the most common subtype of breast cancer, with approximately 40% of these patients harboring a PI3KCA mutation. This mutation is a primary cause of resistance to endocrine therapy and CDK4/6 inhibitors, leading to poorer prognosis for affected patients. At the 2024 CSCO Annual Meeting, Dr. Jiong Wu from Fudan University Shanghai Cancer Center, as the Leading PI, shared the latest findings from the Phase III INAVO120 study. The study demonstrated that the novel PI3K inhibitor, inavolisib, combined with CDK4/6 inhibitors and endocrine therapy, offers improved outcomes for these patients, providing a new treatment option. Based on these results, both the China National Medical Products Administration (CDE) and the U.S. FDA have granted fast-track review status to inavolisib, with hopes of delivering clinical benefits to patients soon. At the CSCO meeting, Oncology Frontier had the opportunity to interview Professor Wu, discussing key insights about inavolisib and providing clinical guidance on this emerging PI3K inhibitor.
Emerging Zoonotic Threat: Avian Chlamydia abortus Linked to Severe Pneumonia in the Netherlands

Emerging Zoonotic Threat: Avian Chlamydia abortus Linked to Severe Pneumonia in the Netherlands

A study in The Lancet Infectious Diseases by Stijn Raven, PhD, Marloes Heijne, PhD, Jeroen Koomen, PhD, and colleagues reports an outbreak of avian Chlamydia abortus causing severe respiratory illness. Three family members were hospitalized with pneumonia, one requiring intensive care. Wild bird exposure was identified as a probable source, with human-to-human transmission also considered. Retrospective analysis found ten similar historical cases, including one fatality. Findings highlight the need for surveillance of this emerging zoonotic threat.